by Natasha Brosseau
Jun 06, 2023Listen to this episode
In today’s episode of the Psychedelic Therapy Frontiers podcast Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Dan Karlin. Dan is Board Certified in Psychiatry, Addiction Medicine, and Clinical Informatics. He currently serves as the Chief Medical Officer of MindMed, a drug development company striving to deliver on the therapeutic potential of psychedelics to address unmet patient needs in psychiatry, addiction, pain, and neurology. Numinus is a trial site for MindMed’s MM-120 or LSD dose-finding study for the treatment of anxiety symptoms, so they discuss that study and what LSD treatment might look like in a post-approval clinical context. They discuss the challenges of mental health care accessibility and affordability, explore the philosophy behind the psychiatric diagnostic system, talk about the societal burden of anxiety, compare and contrast anxiety vs depression, and much more.
(2:35) Dr. Dan Karlin introduces himself and psychedelic studies
(13:34) The path to psychedelic approval
(16:37) Why anxiety?
(21:42) Why LSD?
(24:51) MM-120 and accessibility
(33:21) The burden of anxiety in society
(50:44) MindMed updates
